IL252309B - Compressed bicyclic compounds for disease treatment - Google Patents

Compressed bicyclic compounds for disease treatment

Info

Publication number
IL252309B
IL252309B IL252309A IL25230917A IL252309B IL 252309 B IL252309 B IL 252309B IL 252309 A IL252309 A IL 252309A IL 25230917 A IL25230917 A IL 25230917A IL 252309 B IL252309 B IL 252309B
Authority
IL
Israel
Prior art keywords
disease
treatment
fused bicyclic
bicyclic compounds
compounds
Prior art date
Application number
IL252309A
Other languages
English (en)
Hebrew (he)
Other versions
IL252309A0 (en
Original Assignee
Akarna Therapeutics Ltd
Benjamin Anthony Pratt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akarna Therapeutics Ltd, Benjamin Anthony Pratt filed Critical Akarna Therapeutics Ltd
Publication of IL252309A0 publication Critical patent/IL252309A0/en
Publication of IL252309B publication Critical patent/IL252309B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IL252309A 2014-11-21 2017-05-16 Compressed bicyclic compounds for disease treatment IL252309B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462083031P 2014-11-21 2014-11-21
PCT/US2015/062017 WO2016081918A1 (en) 2014-11-21 2015-11-20 Fused bicyclic compounds for the treatment of disease

Publications (2)

Publication Number Publication Date
IL252309A0 IL252309A0 (en) 2017-07-31
IL252309B true IL252309B (en) 2021-01-31

Family

ID=56014622

Family Applications (1)

Application Number Title Priority Date Filing Date
IL252309A IL252309B (en) 2014-11-21 2017-05-16 Compressed bicyclic compounds for disease treatment

Country Status (17)

Country Link
US (5) US10233187B2 (cg-RX-API-DMAC7.html)
EP (1) EP3221321B1 (cg-RX-API-DMAC7.html)
JP (3) JP7224102B2 (cg-RX-API-DMAC7.html)
KR (1) KR20170117020A (cg-RX-API-DMAC7.html)
CN (2) CN107207513B (cg-RX-API-DMAC7.html)
AU (2) AU2015349687B2 (cg-RX-API-DMAC7.html)
CA (1) CA2968434A1 (cg-RX-API-DMAC7.html)
CL (1) CL2017001289A1 (cg-RX-API-DMAC7.html)
CO (1) CO2017005784A2 (cg-RX-API-DMAC7.html)
ES (1) ES2911293T3 (cg-RX-API-DMAC7.html)
IL (1) IL252309B (cg-RX-API-DMAC7.html)
MX (1) MX370480B (cg-RX-API-DMAC7.html)
MY (1) MY192927A (cg-RX-API-DMAC7.html)
RU (1) RU2706007C2 (cg-RX-API-DMAC7.html)
SA (1) SA517381566B1 (cg-RX-API-DMAC7.html)
SG (2) SG10202010386PA (cg-RX-API-DMAC7.html)
WO (1) WO2016081918A1 (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
US10689383B2 (en) 2014-08-04 2020-06-23 Nuevolution A/S Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
EP3221321B1 (en) * 2014-11-21 2021-12-15 Akarna Therapeutics, Ltd. Fused bicyclic compounds for the treatment of disease
EP3274350A1 (en) * 2015-03-26 2018-01-31 Akarna Therapeutics, Ltd. Fused bicyclic compounds for the treatment of disease
CN109843298A (zh) * 2016-05-25 2019-06-04 阿卡纳治疗学有限公司 利用法尼酯x受体(fxr)调节剂的组合疗法
CA2968836C (en) 2016-06-13 2025-09-02 Gilead Sciences, Inc. FXR MODULATING COMPOUNDS (NR1H4)
KR102269305B1 (ko) 2016-06-13 2021-06-25 길리애드 사이언시즈, 인코포레이티드 Fxr (nr1h4) 조정 화합물
PT3600309T (pt) 2017-03-28 2022-10-03 Gilead Sciences Inc Combinações terapêuticas para o tratamento de doenças hepáticas
RU2019144064A (ru) * 2017-06-02 2021-07-13 Акарна Терапьютикс, Лтд. Конденсированные бициклические соединения
DK3911647T3 (da) 2019-01-15 2024-02-26 Gilead Sciences Inc Isoxazol-forbindelse som FXR-agonist og farmaceutiske sammensætninger, der omfatter en sådan
CN118388474A (zh) 2019-02-19 2024-07-26 吉利德科学公司 Fxr激动剂的固体形式
CN111825653A (zh) * 2019-04-19 2020-10-27 安道麦马克西姆有限公司 取代吡唑类化合物的制备及其作为邻氨基苯甲酰胺前体的用途
JP2022541503A (ja) 2019-07-23 2022-09-26 ノバルティス アーゲー Fxrアゴニストを使用した肝疾患の組み合わせ処置
WO2021014349A1 (en) 2019-07-23 2021-01-28 Novartis Ag Treatment comprising fxr agonists
CN114630681A (zh) 2019-09-03 2022-06-14 诺华股份有限公司 包含actrii受体拮抗剂的肝疾病或障碍的治疗
WO2021053618A1 (en) 2019-09-19 2021-03-25 Novartis Ag Treatment comprising fxr agonists
JP2022550312A (ja) 2019-09-30 2022-12-01 ノバルティス アーゲー Fxrアゴニストの使用を含む処置
KR20220119424A (ko) 2019-12-20 2022-08-29 노파르티스 아게 인테그린 억제제를 사용한 간 질환의 조합 치료
PE20230240A1 (es) 2019-12-20 2023-02-07 Nuevolution As Compuestos activos frente a receptores nucleares
MX2022007265A (es) 2019-12-20 2022-09-09 Nuevolution As Compuestos activos frente a receptores nucleares.
AU2021245397A1 (en) 2020-03-31 2022-10-20 Nuevolution A/S Compounds active towards nuclear receptors
JP7713954B2 (ja) 2020-03-31 2025-07-28 ヌエヴォリューション・アクティーゼルスカブ 核内受容体に対して活性な化合物
AR123313A1 (es) * 2020-08-24 2022-11-16 Adama Makhteshim Ltd Proceso para la preparación de pirazoles sustituidos
WO2022101853A1 (en) 2020-11-16 2022-05-19 Novartis Ag Method of determining liver fibrosis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070015746A1 (en) * 2003-07-23 2007-01-18 X-Ceptor Therapeutics Inc. Azepine derivaties as pharmaceutical agents

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7595311B2 (en) * 2002-05-24 2009-09-29 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents
EA010905B1 (ru) * 2003-09-17 2008-12-30 Янссен Фармацевтика Н.В. Сопряжённые гетероциклические соединения
US20090137554A1 (en) * 2007-10-22 2009-05-28 Wyeth 1,4,5,6-TETRAHYDRO -PYRROLO[2,3-d]AZEPINES AND -IMIDAZO[4,5-d]AZEPINES AS MODULATORS OF NUCLEAR RECEPTOR ACTIVITY
US20090215748A1 (en) * 2007-12-20 2009-08-27 Wyeth FXR agonists for treating vitamin D associated diseases
JP2012503654A (ja) * 2008-09-26 2012-02-09 ワイス・エルエルシー 1,2,3,6−テトラヒドロアゼピノ[4,5−b]インドール−5−カルボキシレート核内受容体阻害剤
US8252826B2 (en) * 2010-03-24 2012-08-28 Hoffmann-La Roche Inc. Cyclopentyl- and cycloheptylpyrazoles
EP3221321B1 (en) * 2014-11-21 2021-12-15 Akarna Therapeutics, Ltd. Fused bicyclic compounds for the treatment of disease
KR20190040140A (ko) * 2016-05-25 2019-04-17 아카나 테라퓨틱스, 엘티디. 질환의 치료를 위한 융합된 비시클릭 화합물

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070015746A1 (en) * 2003-07-23 2007-01-18 X-Ceptor Therapeutics Inc. Azepine derivaties as pharmaceutical agents

Also Published As

Publication number Publication date
AU2020250270B2 (en) 2022-08-25
RU2017121588A (ru) 2018-12-24
CL2017001289A1 (es) 2018-03-02
WO2016081918A1 (en) 2016-05-26
AU2015349687B2 (en) 2020-07-09
MX2017006694A (es) 2018-03-16
MY192927A (en) 2022-09-15
AU2020250270A1 (en) 2020-11-05
JP7224102B2 (ja) 2023-02-17
CN107207513A (zh) 2017-09-26
SG11201703953WA (en) 2017-06-29
CA2968434A1 (en) 2016-05-26
US20250171446A1 (en) 2025-05-29
JP2017535614A (ja) 2017-11-30
CN111662297A (zh) 2020-09-15
US10233187B2 (en) 2019-03-19
US20190308977A1 (en) 2019-10-10
CN107207513B (zh) 2020-07-28
RU2017121588A3 (cg-RX-API-DMAC7.html) 2019-05-21
US20210147426A1 (en) 2021-05-20
JP2023011731A (ja) 2023-01-24
KR20170117020A (ko) 2017-10-20
EP3221321B1 (en) 2021-12-15
IL252309A0 (en) 2017-07-31
CO2017005784A2 (es) 2017-10-31
RU2706007C2 (ru) 2019-11-13
JP2021011482A (ja) 2021-02-04
SG10202010386PA (en) 2020-11-27
EP3221321A4 (en) 2018-04-25
US20170355699A1 (en) 2017-12-14
SA517381566B1 (ar) 2021-05-16
EP3221321A1 (en) 2017-09-27
AU2015349687A1 (en) 2017-06-29
MX370480B (es) 2019-12-16
HK1244802A1 (zh) 2018-08-17
BR112017010627A2 (pt) 2018-02-14
ES2911293T3 (es) 2022-05-18
US20230183247A1 (en) 2023-06-15

Similar Documents

Publication Publication Date Title
IL252309A0 (en) Compressed bicyclic compounds for disease treatment
IL252849A0 (en) Compressed bicyclic compounds for disease treatment
IL253060A0 (en) Pyrimidine compounds are fused to treat hiv
IL261551B (en) bicyclic compounds
IL247452A0 (en) Compounds for treatment of complement mediated disorders
SMT201900172T1 (it) Ammino triazoli sostituiti utili come inibitori della chitinasi umana
IL259281B (en) History of bipyrazolyl used in the treatment of autoimmune diseases
HUE041751T2 (hu) Rákfajták kezeléséhez felhasználható fuzionált biciklusos (hetero)aromás vegyületek
SMT202100082T1 (it) Composti eteroarilici per il trattamento di malattie oftalmiche
ZA201701210B (en) Substituted bicyclic compounds
IL248267B (en) A process for preparing converted cycloserines
IL259297A (en) Heterocyclic compounds for the treatment of disease
IL254572A0 (en) Compressed bicyclic compounds for disease treatment
HUE070257T2 (hu) Vegyületek a lipofuscinhoz kapcsolódó betegségek kezelésére
IL263177A (en) Fused bicyclic compounds for the treatment of disease
PT3166604T (pt) Agentes para o tratamento de doenças infeciosas retrovirais
HK40007136A (en) Fused bicyclic compounds for the treatment of disease
ZA201704589B (en) Compounds for the treatment of cancer

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed